Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters

Therapeutic Methods and Therapies TCIM
Database
Country/Region as subject
Language
Affiliation country
Publication year range
1.
Sci Rep ; 13(1): 16770, 2023 10 05.
Article in English | MEDLINE | ID: mdl-37798424

ABSTRACT

Loquat (Eriobotrya japonica) leaves contain many bioactive components such as ursolic acid (UA) and amygdalin. We investigated the effects of loquat leaf powder and methanol extract in human neuroglioma H4 cells stably expressing the Swedish-type APP695 (APPNL-H4 cells) and C57BL/6 J mice. Surprisingly, the extract greatly enhanced cellular amyloid-beta peptide (Aß) 42 productions in APPNL-H4 cells. Administration of leaf powder increased Aß42 levels after 3 months and decreased levels after 12 months compared to control mice. Leaf powder had no effect on working memory after 3 months, but improved working memory after 12 months. Administration of UA decreased Aß42 and P-tau levels and improved working memory after 12 months, similar to the administration of leave powder for 12 months. Amygdalin enhanced cellular Aß42 production in APPNL-H4 cells, which was the same as the extract. Three-month administration of amygdalin increased Aß42 levels slightly but did not significantly increase them, which is similar to the trend observed with the administration of leaf powder for 3 months. UA was likely the main compound contained in loquat leaves responsible for the decrease in intracerebral Aß42 and P-tau levels. Also, amygdalin might be one of the compounds responsible for the transiently increased intracerebral Aß42 levels.


Subject(s)
Amygdalin , Eriobotrya , Humans , Animals , Mice , Eriobotrya/chemistry , Powders/analysis , Mice, Inbred C57BL , Plant Leaves/chemistry , Plant Extracts/chemistry , Amyloid beta-Peptides/analysis , Ursolic Acid
2.
Int J Med Mushrooms ; 24(9): 15-24, 2022.
Article in English | MEDLINE | ID: mdl-36004706

ABSTRACT

Epidemiologic studies have shown a high prevalence of multiple sclerosis (MS) in Europe and North America, and a low prevalence in East Asia. Mushrooms contain various biological response modifiers (BRMs) and are widely used in traditional Chinese medicine in East Asian countries. To investigate whether mushrooms have potential beneficial effects on MS, we administered mushrooms to cuprizone (bis-cyclohexanone-oxalyldihydrazone, CPZ)-induced MS model mice. This model is used to study the processes of demyelination in the CNS. The CPZ-induced demyelination is involved in the apoptotic death of mature oligodendrocytes, neuroinflammation, and motor dysfunction. Mice were fed a powdered diet containing 5% each mushroom and CPZ diet for 5 weeks, which coincides with peak demyelination. We measured the body weight of the mice, evaluated their motor function using a rotarod, and quantified the myelin levels using Black-Gold II staining. Ganoderma lucidum and Hericium erinaceus treatments showed recovery from weight loss. Pleurotus eryngii, G. lucidum, and Flammulina velutipes treatments significantly improved CPZ-induced motor dysfunction. P. eryngii, G. lucidum, F. velutipes, and H. erinaceus treatments effectively suppressed CPZ-induced demyelination. The four medicinal mushrooms may be promising BRMs for prevention and alleviation of the symptoms of MS.


Subject(s)
Agaricales , Demyelinating Diseases , Multiple Sclerosis , Animals , Cuprizone/toxicity , Demyelinating Diseases/chemically induced , Demyelinating Diseases/drug therapy , Disease Models, Animal , Fruiting Bodies, Fungal , Mice , Mice, Inbred C57BL , Multiple Sclerosis/chemically induced , Multiple Sclerosis/drug therapy
3.
Nutrients ; 12(1)2019 Dec 18.
Article in English | MEDLINE | ID: mdl-31861349

ABSTRACT

Catechins, phytochemicals contained mainly in green tea, exhibit antiviral activity against various acute infectious diseases experimentally. Clinical evidence supporting these effects, however, is not conclusive. We performed a placebo-controlled, single-blind, randomized control trial to evaluate the clinical effectiveness of consumption of catechins-containing beverage for preventing acute upper respiratory tract infections (URTIs). Two hundred and seventy healthcare workers were randomly allocated to high-catechin (three daily doses of 57 mg catechins and 100 mg xanthan gum), low-catechin (one daily dose of 57 mg catechins and 100 mg xanthan gum), or placebo (0 mg catechins and 100 mg xanthan gum) group. Subjects consumed a beverage with or without catechins for 12 weeks from December 2017 through February 2018. The primary endpoint was incidence of URTIs compared among groups using a time-to-event analysis. A total of 255 subjects were analyzed (placebo group n = 86, low-catechin group n = 85, high catechin group n = 84). The URTI incidence rate was 26.7% in the placebo group, 28.2% in the low-catechin group, and 13.1% in the high-catechin group (log rank test, p = 0.042). The hazard ratio (95% confidence interval (CI)) with reference to the placebo group was 1.09 (0.61-1.92) in the low-catechin group and 0.46 (0.23-0.95) in the high-catechin group. These findings suggest that catechins combined with xanthan gum protect against URTIs.


Subject(s)
Catechols/pharmacology , Health Personnel , Respiratory Tract Infections/prevention & control , Tea/chemistry , Adult , Catechols/administration & dosage , Catechols/chemistry , Female , Humans , Male , Middle Aged , Young Adult
4.
J Dermatol ; 46(4): 301-307, 2019 Apr.
Article in English | MEDLINE | ID: mdl-30803017

ABSTRACT

Recently, the USA300 clone, which is a Panton-Valentine leukocidin (PVL)-positive clonal complex 8-staphylococcal cassette chromosome mec type IV (CC8-IV) community-acquired methicillin-resistant Staphylococcus aureus (CA-MRSA) strain, emerged in community and hospital settings in Japan. Hence, clonal types of CA-MRSA strains are predicted to be changing. Nonetheless, long-term surveillance of CA-MRSA has not been conducted in Japan. Here, we investigated the transition and current status of CA-MRSA strains isolated from outpatients with impetigo; the samples were collected between 2007 and 2016 in Kagawa, Japan. The detection rate (22.8%, 488/2139 strains) of MRSA slightly decreased in these 10 years. Molecular epidemiological analyses showed that the prevalence of the CC89-II clone, which is a typical CA-MRSA genotype of causative agents of impetigo, significantly decreased from 48.0% (48/100 strains) in 2007-2009 to 21.9% (16/73 strains) in 2013-2016. By contrast, a non-USA300 CC8-IV clone, which is a highly pathogenic CA-MRSA/J clone, significantly increased in prevalence from 9.0% (9/100 strains) to 32.9% (24/73 strains). The prevalence of PVL-positive CA-MRSA strains increased annually from 2012 (0%) to 2015 (6.7%), whereas only one of these strains turned out to be the USA300 clone. Antibiotic susceptibility data revealed that the rates of resistance to gentamicin and clindamycin among CA-MRSA strains decreased along with the decreased prevalence of the CC89-II clone and increased prevalence of the CA-MRSA/J clone. Our data strongly suggest that the clonal types and antibiotic susceptibility of CA-MRSA isolated from patients with impetigo dramatically changed during the last 10 years in Japan.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Impetigo/microbiology , Methicillin Resistance/genetics , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Staphylococcal Infections/microbiology , Adolescent , Anti-Bacterial Agents/pharmacology , Bacterial Toxins/metabolism , Child , Clindamycin/pharmacology , Clindamycin/therapeutic use , Exotoxins/metabolism , Female , Gentamicins/pharmacology , Gentamicins/therapeutic use , Humans , Impetigo/drug therapy , Impetigo/epidemiology , Japan/epidemiology , Leukocidins/metabolism , Male , Methicillin-Resistant Staphylococcus aureus/drug effects , Methicillin-Resistant Staphylococcus aureus/genetics , Methicillin-Resistant Staphylococcus aureus/metabolism , Microbial Sensitivity Tests , Molecular Epidemiology , Prevalence , Staphylococcal Infections/drug therapy , Staphylococcal Infections/epidemiology
5.
Mod Rheumatol ; 21(5): 488-94, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21347801

ABSTRACT

The aim of this study was to clarify the reproducibility of the Japanese Ministry of Health, Labor and Welfare (JMHLW) type classification for osteonecrosis of the femoral head. We performed inter-observer and intra-observer trials using 40 sets of magnetic resonance imagings, 20 of which were produced by a 0.5 Tesla (T) superconductive unit and the other 20 produced by a 1.5 T unit, in patients with non-collapsed and asymptomatic osteonecrosis of the femoral head (JMHLW stage 1 or 2). The JMHLW type classification (A, B, C1, or C2) was determined from T1-weighted coronal images at the center of the femoral head. Six orthopedic surgeons independently assessed all 40 images twice, with an interval of 4-5 weeks between sessions. Regarding inter-observer reliability, the percent agreement was 85% and weighted kappa was 0.709 for 0.5 T, versus a percent agreement of 82% and weighted kappa of 0.724 for 1.5 T. Regarding intra-observer reliability, the percent agreement was 82% and weighted kappa was 0.780 for 0.5 T versus a percent agreement of 80% and weighted kappa of 0.800 for 1.5 T. Inter-observer and intra-observer reliabilities did not differ significantly between the 0.5 and 1.5 T units. The JMHLW type classification provided high inter-observer and intra-observer reliabilities.


Subject(s)
Femur Head Necrosis/classification , Femur Head Necrosis/pathology , Femur Head/pathology , Magnetic Resonance Imaging/standards , Adolescent , Adult , Female , Humans , Japan , Magnetic Resonance Imaging/statistics & numerical data , Male , National Health Programs/standards , Observer Variation , Reproducibility of Results , Young Adult
SELECTION OF CITATIONS
SEARCH DETAIL